Literature DB >> 2182959

Objective assessment of clonidine analgesia in man and influence of naloxone.

H C Porchet1, P Piletta, P Dayer.   

Abstract

Experimental data indicate that clonidine can induce marked analgesia. We characterized this effect in healthy volunteers and investigated possible links with the opioid peptide system by means of naloxone antagonism. According to a cross-over, double-blind, placebo-controlled design, 10 subjects received oral and i.v. placebo or clonidine (0.2 mg p.o.) or clonidine and naloxone (2.8 mg i.v. in 5 h). Analgesia was assessed by measurement of the subjective pain threshold (visual analog scale) and the objective nociceptive flexion reflex (R III) threshold after transcutaneous electrical stimulations. A correlation was observed between subjective and objective thresholds (r: 0.78). Oral clonidine alone or with naloxone increased subjective and objective pain thresholds for at least 4 hours (p less than 0.01, ANOVA). Naloxone tended to reinforce clonidine analgesia. Only moderate and well tolerated side-effects were observed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2182959     DOI: 10.1016/0024-3205(90)90022-j

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Pharmacokinetic-pharmacodynamic modeling of the effects of clonidine on pain threshold, blood pressure, and salivary flow.

Authors:  H C Porchet; P Piletta; P Dayer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Catastrophizing is related to pain ratings, but not nociceptive flexion reflex threshold.

Authors:  Christopher R France; Janis L France; Mustafa al'Absi; Christopher Ring; David McIntyre
Journal:  Pain       Date:  2002-10       Impact factor: 7.926

3.  Selective REM Sleep Deprivation Improves Expectation-Related Placebo Analgesia.

Authors:  Florian Chouchou; Jean-Marc Chauny; Pierre Rainville; Gilles J Lavigne
Journal:  PLoS One       Date:  2015-12-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.